010683053 Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.45 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.41 |
| 11 Month Change | -7.81% |
| 3 Month Change | -11.34% |
| 1 Year Change | -3.85% |
| 33 Year Change | 5.88% |
| 5 Year Change | 6.87% |
| Change since IPO | 121.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 010683053 | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -0.8% | -0.7% | -1.1% |
| 1Y | -3.8% | 12.3% | 8.2% |
Return vs Industry: 010683053 underperformed the Swiss Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: 010683053 underperformed the Swiss Market which returned 7% over the past year.
Price Volatility
| 010683053 volatility | |
|---|---|
| 010683053 Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 3.0% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 6.9% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: 010683053 has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine 010683053's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
| 010683053 fundamental statistics | |
|---|---|
| Market cap | CHF 222.01b |
| Earnings (TTM) | CHF 10.82b |
| Revenue (TTM) | CHF 56.29b |
20.5x
P/E Ratio3.9x
P/S RatioIs 010683053 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 010683053 income statement (TTM) | |
|---|---|
| Revenue | US$63.17b |
| Cost of Revenue | US$14.79b |
| Gross Profit | US$48.39b |
| Other Expenses | US$36.24b |
| Earnings | US$12.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
| Earnings per share (EPS) | 4.80 |
| Gross Margin | 76.59% |
| Net Profit Margin | 19.23% |
| Debt/Equity Ratio | 85.6% |
How did 010683053 perform over the long term?
See historical performance and comparison